Pet Pharmaceuticals
APAC · 3 shared keywords
Updated
Reviewed by Vidhi Upadhyay
APAC Veterinary Drugs Market Industry Trends and Forecast to 2034: Segmented by (Product, Animal, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$8.77 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $7.85 Bn | — | — |
| 2025 (base) | $8.49 Bn | +$643.4 Mn | — |
| 2026 (forecast) | $9.19 Bn | +$696.2 Mn | +8.2% |
| 2027 (forecast) | $9.94 Bn | +$753.3 Mn | +17.1% |
| 2028 (forecast) | $10.75 Bn | +$815.0 Mn | +26.7% |
| 2029 (forecast) | $11.64 Bn | +$881.9 Mn | +37.1% |
| 2030 (forecast) | $12.59 Bn | +$954.2 Mn | +48.3% |
| 2031 (forecast) | $13.62 Bn | +$1.03 Bn | +60.5% |
| 2032 (forecast) | $14.74 Bn | +$1.12 Bn | +73.6% |
| 2033 (forecast) | $15.95 Bn | +$1.21 Bn | +87.9% |
| 2034 (forecast) | $17.26 Bn | +$1.31 Bn | +103.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $8.49 Bn placeholder estimate |
|---|---|
| Forecast, 2034 | $17.26 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 8.2% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Product and animal (see all) |
| Key players | Zoetis, Inc, Elanco, Merck & Co., Inc., Boehringer Ingelheim GmbH, Ceva Sante Animale and 1 more (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Veterinary drugs are the medicines given to pets and farm animals to treat or prevent disease and pain.
Key segments of the veterinary drugs market include product (Anti-Infectives, Anti-Parasitics and Anti-Inflammatories) and animal (Dogs, Cats and Cattle).
More pet ownership, spending on pet care, rising demand for meat and milk, and concern about animal disease are driving the veterinary drugs market.
Long-acting treatments, tests that find disease early and growing pet spending in emerging countries give the veterinary drugs market room to grow.
Rules on antibiotic use in farm animals, high drug prices for pet owners and shortages of vets in rural areas hold back the veterinary drugs market.
The veterinary drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In some of the countries we cover here, medicines are approved by TGA (Australia)[1], NMPA (China)[2], Drug Office (Hong Kong)[3], CDSCO (India)[4], PMDA (Japan)[5], NPRA (Malaysia)[6], Medsafe (New Zealand)[7], FDA Philippines (Philippines)[8], HSA (Singapore)[9], Thai FDA (Thailand)[10], BPOM (Indonesia)[11], DRAP (Pakistan)[12], MFDS (South Korea)[13] and Drug Administration of Vietnam (Vietnam)[14]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[15], basic medical insurance (China)[16], the Hospital Authority (Hong Kong)[17], Ayushman Bharat PM-JAY (India)[18], public health insurance (Japan)[19], subsidised public care (Malaysia)[20], Pharmac (New Zealand)[21], PhilHealth (Philippines)[22], MediShield Life (Singapore)[23], the Universal Coverage Scheme (Thailand)[24], JKN (BPJS Kesehatan) (Indonesia)[25], out of pocket and Sehat Sahulat (Pakistan)[26], National Health Insurance (South Korea)[27] and social health insurance (Vietnam)[28].
[1] Therapeutic Goods Administration. Checked 14 Nov 2026.
[2] National Medical Products Administration. Checked 14 Nov 2026.
[3] Drug Office, Department of Health. Checked 14 Nov 2026.
[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
[6] National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.
[7] Medsafe. Checked 14 Nov 2026.
[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.
[9] Health Sciences Authority. Checked 14 Nov 2026.
[10] Thai Food and Drug Administration. Checked 14 Nov 2026.
[11] National Agency of Drug and Food Control (BPOM). Checked 19 Nov 2026.
[12] Drug Regulatory Authority of Pakistan (DRAP). Checked 19 Nov 2026.
[13] Ministry of Food and Drug Safety. Checked 19 Nov 2026.
[14] Drug Administration of Vietnam. Checked 19 Nov 2026.
[15] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
[16] National Healthcare Security Administration. Checked 14 Nov 2026.
[17] Hospital Authority. Checked 14 Nov 2026.
[18] National Health Authority (PM-JAY). Checked 14 Nov 2026.
[19] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
[20] Ministry of Health Malaysia. Checked 14 Nov 2026.
[21] Pharmac. Checked 14 Nov 2026.
[22] PhilHealth. Checked 14 Nov 2026.
[23] CPF Board, MediShield Life. Checked 14 Nov 2026.
[24] National Health Security Office. Checked 14 Nov 2026.
[25] BPJS Kesehatan. Checked 19 Nov 2026.
[26] Ministry of National Health Services, Regulations and Coordination. Checked 19 Nov 2026.
[27] Health Insurance Review and Assessment Service (HIRA). Checked 19 Nov 2026.
[28] Vietnam Social Security. Checked 19 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for veterinary drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.
APAC · 3 shared keywords
APAC · 1 shared keyword
APAC · 1 shared keyword
APAC · 1 shared keyword
APAC · 1 shared keyword
APAC · 1 shared keyword
OTC & Nutraceuticals · APAC
Healthcare Services · APAC
Medical Devices · APAC
Digital Health · APAC
Healthcare Services · APAC
Public Health · Global